Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine · 2025-01 · 27 (1) · 101243
DOI: 10.1016/j.gim.2024.101243 ↗Kurz gefasst
Leitlinie in der Zeitschrift Genetics in Medicine, 2025-01. Verfasst von Tuya Pal und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Germ-Line Mutation, Genetic Predisposition to Disease, Heterozygote. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 152 Literaturangaben. Gefördert von: National Cancer Institute, Division of Cancer Epidemiology and Genetics, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous variable, influenced by family history and other modifiers. ATM GPV heterozygotes should generally be offered enhanced breast surveillance according to their personalized risk estimate and country-specific guidelines and, generally, risk-reducing mastectomy is not recommended. Prostate cancer surveillance should be considered. Pancreatic cancer surveillance should be considered based on assessment of family history, ideally as part of a clinical trial, with existence of country-specific guidelines. For ATM GPV heterozygotes who develop cancer, radiation therapy decisions should not be influenced by the genetic result. Although poly-adenosine diphosphate ribose polymerase inhibitors are licensed for use in metastatic castration-resistant prostate cancer and ATM GPVs, the evidence-base is currently weak. CONCLUSION: Systematic prospective data collection is needed to establish the spectrum of ATM-associated cancer and determine the outlines of surveillance, response to cancer treatment, and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN.
- Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.
- Department of Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ.
- Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Hospital Campus, Barcelona, Spain.
- Departments of Human Genetics, Oncology and Medicine, McGill University, Montréal, Québec, Canada.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Förderung
- National Cancer Institute
- Division of Cancer Epidemiology and Genetics
- NIHR Cambridge Biomedical Research Centre
- Breast Cancer Research Foundation
- AstraZeneca
Zitieren
APA
Pal, T., Schon, K. R., Astiazaran-Symonds, E., Balmaña, J., Foulkes, W. D., James, P., Klugman, S., Livinski, A. A., Mak, J. S., Ngeow, J., Voian, N., Wick, M. J., Hanson, H., Stewart, D. R., Tischkowitz, M., & ACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.net (2025). Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 27(1), 101243. https://doi.org/10.1016/j.gim.2024.101243
Vancouver
Pal T, Schon KR, Astiazaran-Symonds E, Balmaña J, Foulkes WD, James P, et al. Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2025;27(1):101243. doi:10.1016/j.gim.2024.101243
BibTeX
@article{Pal2025,
author = {Pal, Tuya and Schon, Katherine R and Astiazaran-Symonds, Esteban and Balmaña, Judith and Foulkes, William D and James, Paul and Klugman, Susan and Livinski, Alicia A and Mak, Julie S and Ngeow, Joanne and Voian, Nicoleta and Wick, Myra J and Hanson, Helen and Stewart, Douglas R and Tischkowitz, Marc and ACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.net, ACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.net},
title = {Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)},
journal = {Genetics in Medicine},
year = {2025},
volume = {27},
number = {1},
pages = {101243},
doi = {10.1016/j.gim.2024.101243}
}
EUVIMED